Author

Martin Bortlík 1

1 Charles University, Prague, Czech Republic

INCIDENCE AND INITIAL DISEASE COURSE OF INFLAMMATORY BOWEL DISEASES IN 2011 IN EUROPE AND AUSTRALIA: RESULTS OF THE 2011 ECCO-EPICOM INCEPTION COHORT

Zsuzsanna Vegh, Johan Burisch, Natalia Pedersen, IOANNIS (JOHN) KAIMAKLIOTIS, Dana Duricova, Martin Bortlík, Søren Avnstrøm, Kristoffer Kofod Vinding, Jóngerð Olsen, Kari Rubek Nielsen, Konstantinos H. Katsanos, Peter L Lakatos, Doron Schwartz, Shmuel Odes, Lupinacci Guido, Angelo De Padova, Laimas Jonaitis, Limas Kupcinsk

INFLIXIMAB BIOSIMILAR CT-P13 THERAPY IS EFFECTIVE IN MAINTAINING ENDOSCOPIC REMISSION IN ULCERATIVE COLITIS – RESULTS FROM MULTICENTRE OBSERVATIONAL COHORT

Klaudia Farkas, Anita Balint, Mariann Rutka, Martin Kolar, Martin Bortlík, Dana Duricova, Veronika Hruba, Martin Lukas, Katarina Mitrova, Karin Malíčková, Milan Lukas, Zoltan Gabor Szepes, Ferenc Nagy, Karoly Palatka, Szilvia Lovas, Zsuzsanna Vegh, Zsuzsanna Kürti, Agnes Anna Csontos, Pal Miheller, Renáta Bor, Ágnes Mil

LONG-TERM FUNCTIONAL OUTCOME AND QUALITY OF LIFE AFTER RESTORATIVE PROCTOCOLECTOMY AND ILEAL - POUCH ANAL ANASTOMOSIS IN ULCERATIVE COLITIS PATIENTS

Marta Kostrejova, Dana Duricova, Milan Lukas, Petr Pekny, Martin Bortlík, Josef Dosedel, Alena Fialova, Richard Sequens

NO DIFFERENCE IN IMMUNOGENICITY OF THE ORIGINAL AND BIOSIMILAR INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Karin Malíčková, Dana Duricova, Martin Kolar, Martin Bortlík, Veronica Hruba, Nadezda Machkova, Katarina Mitrova, Martin Lukas, Milan Lukas

Point-of-care testing system for fecal calprotectin detection in the telemonitoring of patients with inflammatory bowel diseases

Karin Malíčková, Veronika Pešinová, Martin Bortlík, Dana Duricova, Nadezda Machkova, Veronika Hruba, Martin Lukas, Martin Vašátko, Milan Lukas

Serum trough SB5 levels: A comparison of two different immunoassays for the monitoring of biosimilar adalimumab treatment in patients with inflammatory bowel disease

Karin Malíčková, Martin Bortlík, Dana Duricova, Nadezda Machkova, Veronika Hruba, Martin Lukas, Martin Vašátko, Katarina Mitrova, Marta Kostrejova, Milan Lukas

SKIN SIDE-EFFECTS OF BIOLOGIC THERAPY AND SYSTEMIC DRUGS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Katerina Juzlova, Karolina Koblova, Jana Hercogova, Martin Bortlík, Dana Duricova, Martin Kolar, Milan Lukas

Skin side-effects of biologic therapy and systemic drugs in patients with inflammatory bowel diseases

Martin Bortlík

SWITCHING OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE FROM ORIGINAL INFLIXIMAB (REMICADE®) TO BIOSIMILAR INFLIXIMAB (REMSIMA?) IS EFFECTIVE AND SAFE ? ONE-YEAR FOLLOW-UP

Martin Kolar, Dana Duricova, Martin Bortlík, Veronica Hruba, Nadezda Machkova, Katarina Mitrova, Karin Malíčková, Martin Lukas, Milan Lukas

Tofacitinib induction efficiency and intracellular cytokine dynamics in ulcerative colitis: results from clinical practice

Martin Kolar, Martin Lukas, Karin Malíčková, Martin Bortlík, Dana Duricova, Nadezda Machkova, Veronika Hruba, Katarina Mitrova, Martin Vašátko, Milan Lukas

Item 11 - 20 / 31
1
2
3 4